{
    "nctId": "NCT05359783",
    "briefTitle": "Sentinel Node Localization and Staging With Low Dose Superparamagnetic Iron Oxide",
    "officialTitle": "Sentinel Node Localization and Staging With Low Dose Superparamagnetic Iron Oxide-enhanced Magnetic Resonance Imaging and Magnetic Probe in Patients With Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer, Sentinel Lymph Node",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "Sentinel lymph node detection rate compared to Tc99m and blue dye",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female aged above 18 years\n2. Signed and dated written informed consent before the start of specific protocol procedures\n3. Histologically confirmed breast cancer planned for breast conserving surgery and sentinel lymph node biopsy\n\nExclusion Criteria:\n\n1. Pregnant or breast-feeding\n2. Iron overload disease\n3. Known hypersensitivity to iron, dextran compounds or blue dye.\n4. Inability to understand given information and give informed consent or undergo study procedures\n5. MRI (subgroup of patients): Conditions contraindicating MRI including, but not limited to, BMI \\> 40 kg/m2, claustrophobia, metallic implants or internal electrical devices (e.g., pacemaker) and permanent makeup or tattoos which in the Investigator's opinion might jeopardise the patient's safety or imaging.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}